Cabaletta Bio, Inc.
- CABA
- NASDAQ
- Biotechnology
- T Cell Therapy
- Autoimmune Disease Treatment
$1.41
Today −9.03%Quote Oct 16, 2026, 08:00 PM UTC
−45.35%over the last month
Max drawdown −45.3%From 1-month high −45.3%3 months −48.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$239.1M
Quote Oct 16
Next earnings
Nov 9
Expected, not confirmed
Analyst target
$16.33
+1058.2% from here
Floor
$1.39
1.6% below price
Where the price sits
12 analysts
Analyst range, low to high
$3.00$32.00
- Price $1.41
- Resistance $1.55
- Consensus $16.33
The price is just above its floor. Analysts' average target sits about 1058% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CABAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
156
Founded
2017